Envestnet Asset Management
ARQT icon

Envestnet Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Envestnet Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Sell
9,198
-19,710
-68% -$459K ﹤0.01% 4566
2026
Q1 		$681K Buy
28,908
+2,377
+9% +$60.7K ﹤0.01% 3714
2025
Q4 		$770K Buy
+26,531
New +$679K ﹤0.01% 3423

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Envestnet Asset Management's ARQT Position: Q2 2026 in Review

Envestnet Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 68% in Q2 2026, selling an estimated $459K and leaving 9,198 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #4566.

Envestnet Asset Management first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $770K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Envestnet Asset Management held 9,198 shares of Arcutis Biotherapeutics worth $241K as of Q2 2026.
  • Envestnet Asset Management sold 19,710 Arcutis Biotherapeutics shares in Q2 2026, an estimated $459K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4566 holding.
  • Envestnet Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Envestnet Asset Management's Arcutis Biotherapeutics position peaked at $770K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.